Navigation Links
Replidyne Announces 2007 Fourth Quarter and Full Year Results
Date:2/26/2008

er full year contingent supply agreement costs related to the faropenem program and $1.5 million of product acquisition cost in 2006 to complete the purchase of tRNA synthetase technology from GlaxoSmithKline which includes Replidyne's C. difficile program and REP8839.

Sales, general and administrative expenses for the fourth quarter of 2007 were $3.2 million compared to $3.5 million in the fourth quarter of 2006 reflecting lower marketing study expenses in the 2007 quarter. Included in the 2007 quarter result was $0.6 million related to the organizational restructuring implemented on December 10, 2007. Full year 2007 selling, general and administrative expenses were $13 million compared to $12.2 million in 2006 reflecting increased full year compensation costs, restructuring expense, and increased professional fees related to public company compliance.

Investment income for the fourth quarter of 2007 was $1.2 million compared to $1.7 million for the fourth quarter of 2006, primarily reflecting lower cash balances available for investment in the 2007 period. Full year 2007 investment income was $5.5 million compared to $6.0 million 2006.

As reported in its 2006 results, through July 3, 2006 Replidyne recorded dividends due to preferred shareholders of $5.4 million. All outstanding preferred stock and accumulated dividends were converted into common stock upon closing of the initial public offering on July 3, 2006 and no preferred stock or accrued dividends were outstanding after that date.

Conference Call Information

Replidyne will host a conference call and webcast today, February 26, 2008, at 4:45 P.M. EST to discuss 2007 fourth quarter and full year financial results and update the Company's expectations. Callers may participate in the conference call by dialing 866-510-0707 (domestic) or 617-597-5376 (international), and providing the passcode 33794809. To access the live webcast, log on to the Company's website at

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... AVIV, Israel , May 4, 2015  Tikcro ... filed its annual report on Form 20-F for the ... Securities and Exchange Commission ("SEC"). The annual report on ... the development of antibodies in the area of cancer ... with superior qualities of high specificity and binding in ...
(Date:5/4/2015)... 4, 2015 /PRNewswire/ - The Fight Against Cancer ... to announce the formation of Turnstone Biologics Inc. ... for cancer that harness the patient,s own immune ... collaboration between the Children,s Hospital of ... University, the Ontario Institute for Cancer Research (OICR), ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Achieved primarily ... produces slides that boast 10 to 100x better detail ... the capabilities of all existing light microscopy methods, it ... micrographs were chosen as the frame of reference because ... , The goal from the earliest discovery days ...
(Date:5/4/2015)... , May 4, 2015 ... thousands of med students prepare for the United States ... world-leading provider of scientific, technical and medical information products ... free MOOC (Massive Open Online Course) designed to help ... Examination (USMLE) Step 1, the first and most daunting ...
Breaking Biology Technology:Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3
... Therapeutics, Inc. today presented final results from its Phase ... of exenatide) for the treatment of type 2 diabetes ... the Study of Diabetes in Vienna, Austria. Results of ... (FPG) within 24 hours of the start of treatment ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a conference call and webcast on Wednesday, October 28, at ... , , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay ...
... 30 InteKrin Therapeutics Inc. announced today positive results for ... 45th European Association for the Study of Diabetes ... will be presented at 1:45 PM Friday, October 2, 2009 ... His presentation is entitled "Impact of INT131 Besylate, a Selective ...
Cached Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 2Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 4Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 5BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 2
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... of field work by associate professor James Davis Reimer and ... in Okinawa, Japan has found two new species of ... The species belong to the genus Neozoanthus , which ... Indian Ocean. Surprisingly, the new species were found in the ...
... of the journal Environmental Health Perspectives and ... Environment" a companion report by the Dartmouth-led Coastal and ... mercury released into the air and then deposited into ... U.S. and globally. Over the past century, ...
... 2012 Academic, Industry Professionals can use ... Ocean Thin Films is calling for grant proposals featuring ... SpectroCam is an imaging system that integrates scientific-grade sensors ... gives participants the unique opportunity to add a high-end ...
Cached Biology News:An ocean away: 2 new encrusting anemones found in unexpected locations 2Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings 2Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings 3Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings 4Ocean Thin Films Announces Multispectral Imaging Research Grant Program 2Ocean Thin Films Announces Multispectral Imaging Research Grant Program 3
...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 9(S)-HODE ... by the lipoxygenation of linoleic acid in both ... atherosclerotic plaques, as an esterified component of membrane ...
Biology Products: